Leader in Biomolecular Solutions for Life Science

Human RANKL Monoclonal Antibody

Catalog No.: YR0036



Basic Information

Molecular Weight 150 kDa

Endotoxin <1EU/mg (<0.001EU/µg)Determined by LAL gel clotting assay

Sterility 0.2 μm filtration

Aggregation <5% Determined by SECP

Purity >95% Determined by SDS-PAGE

Background

Denosumab, a fully human monoclonal antibody, inhibits the RANKL (RANK ligand) protein, the primary signal for bone removal. Denosumab can be used for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone.

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical P K and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone Denosumab Biosimilar **Isotype** Human IgG2 kappa

Immunogen

Human RANK Ligand

RecommendedIsotype Control(s)

In Vivo Grade Recombinant Human IgG2 Kappa Isotype Control Antibody

Recommended Dilution Buffer

1×PBS pH 5.2

Contact

6	400-999-6126
\times	cn.market@abclonal.com.cn
€	www.abclonal.com.cn

Product Information

Production Purified from cell culture supernatant in an animal-free facility

Purification Protein A or G purification

Storage

Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)